Real World Efficacy of Pembrolizumab of as a 1st Line Treatment in Metastatic Non-Small Cell Lung Cancer with PD-L1 High Expression

被引：0
|
作者：
Kasahara, K. [1 ]
Sone, T. [1 ]
Nishi, K. [2 ]
Shibata, K. [3 ]
Araya, T. [4 ]
Shirasaki, H. [5 ]
Yoneda, T. [6 ]
Kase, K. [7 ]
Nishikawa, S. [1 ]
Kimura, H. [1 ]
Tambo, Y. [1 ]
机构：
[1] Kanazawa Univ, Resp Med, Kanazawa, Ishikawa, Japan
[2] Ishikawa Prefectural Cent Hosp, Resp Med, Kanazawa, Ishikawa, Japan
[3] Kouseiren Takaoka Hosp, Med Oncol, Takaoka, Toyama, Japan
[4] Natl Hosp Org Kanazawa Med Ctr, Resp Med, Kanazawa, Ishikawa, Japan
[5] Fukui Ken Saiseikai Hosp, Resp Med, Fukui, Japan
[6] Komatsu Municipal Hosp, Resp Med, Komatsu, Japan
[7] Keiju Med Ctr, Resp Med, Nanao, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Pembrolizumab; 1st line treatment; PD-L1 high expression;
D O I：
10.1016/j.jtho.2019.08.953
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.04-50
引用
收藏
页码：S460 / S460
页数：1
相关论文
共 50 条
  • [31] The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer
    Ito, Kentaro
    Miura, Satoru
    Sakaguchi, Tadashi
    Murotani, Kenta
    Horita, Nobuyuki
    Akamatsu, Hiroaki
    Uemura, Kohei
    Morita, Satoshi
    Yamamoto, Nobuyuki
    LUNG CANCER, 2019, 128 : 113 - 119
  • [32] Efficacy of PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer and brain metastases: A real-world retrospective study in China
    Sheng, Jiamin
    Li, Hui
    Yu, Xiaoqing
    Yu, Sizhe
    Chen, Kaiyan
    Pan, Guoqiang
    Xie, Mingying
    Li, Na
    Zhou, Zichao
    Fan, Yun
    THORACIC CANCER, 2021, 12 (22) : 3019 - 3031
  • [33] Treatment selection and real-world analysis of immunotherapy with or without chemotherapy in PD-L1-high metastatic non-small cell lung cancer
    Smith, Samuel
    Kao, Steven
    Boyer, Michael
    Franco, Michael
    Moore, Melissa
    INTERNAL MEDICINE JOURNAL, 2024, 54 (08) : 1337 - 1343
  • [34] PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability
    Munari, Enrico
    Zamboni, Giuseppe
    Marconi, Marcella
    Sommaggio, Marco
    Brunelli, Matteo
    Martignoni, Guido
    Netto, George J.
    Moretta, Francesca
    Mingari, Maria Cristina
    Salgarello, Matteo
    Terzi, Alberto
    Picece, Vincenzo
    Pomari, Carlo
    Lunardi, Gianluigi
    Cavazza, Alberto
    Rossi, Giulio
    Moretta, Lorenzo
    Bogina, Giuseppe
    ONCOTARGET, 2017, 8 (52): : 90123 - 90131
  • [35] Characteristics and Predictive Value of PD-L1 Status in Real-World Non-Small Cell Lung Cancer Patients
    Tseng, Jeng-Sen
    Yang, Tsung-Ying
    Wu, Chih-Ying
    Ku, Wen-Hui
    Chen, Kun-Chieh
    Hsu, Kuo-Hsuan
    Huang, Yen-Hsiang
    Su, Kang-Yi
    Yu, Sung-Liang
    Chang, Gee-Chen
    JOURNAL OF IMMUNOTHERAPY, 2018, 41 (06) : 292 - 299
  • [36] Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non–small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study
    Hayato Kawachi
    Motohiro Tamiya
    Akihiro Tamiya
    Seigo Ishii
    Katsuya Hirano
    Hirotaka Matsumoto
    Yasushi Fukuda
    Toshihide Yokoyama
    Ryota Kominami
    Daichi Fujimoto
    Kazutaka Hosoya
    Hidekazu Suzuki
    Tomonori Hirashima
    Masaki Kanazu
    Nobuhiko Sawa
    Junji Uchida
    Mitsunori Morita
    Takeshi Makio
    Satoshi Hara
    Toru Kumagai
    Investigational New Drugs, 2020, 38 : 211 - 218
  • [37] Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer
    Rocco, Danilo
    Malapelle, Umberto
    Del Re, Marzia
    Della Gravara, Luigi
    Pepe, Francesco
    Danesi, Romano
    Troncone, Giancarlo
    Gridelli, Cesare
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2020, 16 (02) : 87 - 96
  • [38] First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study
    Amrane, Karim
    Geier, Margaux
    Corre, Romain
    Lena, Herve
    Leveiller, Guillaume
    Gadby, Florence
    Lamy, Regine
    Bizec, Jean-Louis
    Goarant, Eric
    Robinet, Gilles
    Gouva, Sylvie
    Quere, Gilles
    Abgral, Ronan
    Schick, Ulrike
    Bernier, Cyril
    Chouaid, Christos
    Descourt, Renaud
    CANCER MEDICINE, 2020, 9 (07): : 2309 - 2316
  • [39] PD-1/PD-L1 Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
    Bagley, Stephen J.
    Bauml, Joshua M.
    Langer, Corey J.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (10) : 676 - 683
  • [40] Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC)
    Zeng, Tian
    Qin, Qin
    Bian, Zhiheng
    Li, Jianjun
    ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2019, 47 (01) : 4194 - 4201
12345